Related Experiment Video

Updated: Aug 29, 2026

Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry (CE-ICP-MS) for Quantification of Iron Redox Species (Fe(II), Fe(III))
04:48

Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry (CE-ICP-MS) for Quantification of Iron Redox Species (Fe(II), Fe(III))

Published on: May 4, 2020

Conceptual and practical advances in the measurement and clinical management of lead toxicity

J H Graziano1

  • 1Division of Environmental Sciences, Columbia University Medical Center, New York, New York 10032.

Neurotoxicology
|January 1, 1993
PubMed

Insights

The FDA approved 2,3-dimercaptosuccinic acid (DMSA) for treating children with high blood lead levels. However, its use for lower levels requires further study to balance risks and benefits.

Area of Science:

  • Pediatric Toxicology
  • Environmental Health
  • Pharmacology

Background:

  • Elevated blood lead (BPb) concentrations in children pose significant health risks.
  • The FDA approved 2,3-dimercaptosuccinic acid (DMSA) in 1991 for treating children with BPb ≥ 45 µg/dL.
  • DMSA offers a safer, orally active, and specific treatment option, simplifying management of lead poisoning.

Purpose of the Study:

  • To discuss the risks and benefits of DMSA pharmacologic intervention in children with elevated BPb.
  • To address concerns regarding the potential overuse of DMSA for lower BPb concentrations ( < 45 µg/dL).
  • To evaluate the necessity and justification for treating children with BPb levels below 45 µg/dL.

Main Methods:

  • Literature review and discussion of existing data on DMSA efficacy and safety.
  • Analysis of current guidelines and their potential impact on clinical practice.
  • Identification of knowledge gaps regarding DMSA treatment for lower BPb levels.

Main Results:

  • DMSA is an effective and relatively safe treatment for children with BPb ≥ 45 µg/dL.
  • The risks and benefits of DMSA treatment for children with BPb < 45 µg/dL are not well-established.
  • Current public health aims to lower BPb may inadvertently lead to the treatment of children with lower levels.

Conclusions:

  • Further research, including randomized, placebo-controlled trials, is essential to assess the risks and benefits of DMSA for lower BPb concentrations.
  • Clinical decisions regarding DMSA use in children with BPb < 45 µg/dL require careful consideration of uncertain outcomes.
  • Evidence-based guidelines are needed to ensure appropriate pharmacologic intervention for pediatric lead exposure.

More Related Videos

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

Rearing the Cabbage White Butterfly (Pieris rapae) in Controlled Conditions: A Case Study with Heavy Metal Tolerance08:08

Rearing the Cabbage White Butterfly (Pieris rapae) in Controlled Conditions: A Case Study with Heavy Metal Tolerance

Published on: August 18, 2023

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.